Retatrutide is an investigational triple incretin receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, producing appetite suppression, enhanced insulin secretion, and increased energy expenditure, though long-term safety and cardiovascular outcome data are not yet available
A proactive discussion enables faster, safer decision-making when you're acutely ill and less able to navigate complex medical choices
Your monthly subscription covers the cost of your clinician, your medication, your at-home lab kits and shippingno surprise bills or copays
This multidimensional therapeutic approach exemplifies the convergence of bioinorganic chemistry and phytopharmacology in developing precision oncology agents
In general, you may qualify if you meet the following: You have commercial/private insurance Patients with employer-sponsored or marketplace insurance may be eligible
Have imaging/endoscopy or gastric emptying studies showing delayed emptying or obstruction